Record margins via operating leverage; organic growth acceleration stalled
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
₹300 Cr EBITDA guidance reaffirmed; Q1 run-rate ₹76.96 Cr annualizes to ~₹308 Cr, above floor.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong operational execution with record EBITDA margin (34.3%) driven by genuine operating leverage. However, guidance reaffirmed not raised, organic growth below targets (6.9% Corp Learning, low-teens ex-Unbound), and Unbound integration success still unproven long-term. Conviction present but execution risk on organic acceleration remains key dependency.
₹224.2 Cr
Revenue · +20.4% YoY₹50.4 Cr
Reported PAT · +43% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Strongest Q1 in Company's history on every line
MET₹224.2 Cr revenue, ₹76.96 Cr EBITDA, ₹50.4 Cr PAT, all-time Q1 highs confirmed
Operating leverage: revenue +20%, EBITDA +53%, headcount <3%
METVerified: 20.4% revenue, 53% EBITDA, headcount rise minimal; margin expanded 730 bps
Unbound performing as underwrote: recurring, high-margin subscription
MET$800K/month = ~₹71 Cr ARR, 18-20% EBITDA margin, institutional base growing
Corporate Learning turnaround in progress
OVERSTATEDMargin jumped 16.9%→25.3%, but organic growth only 6.9% vs 12% target. Cost restructuring, not volume-led
Rule of 50: sustainable operating model
METQ1 score 54 (20% growth + 34% margin), but explicitly not guaranteed every quarter. AJE reset & Unbound tailwinds ephemeral
Earnings quality
What changed since the last call
EBITDA margin +730 bps to 34.3%
UpgradeQ1 vs YoY prior 27%. Not formally guided but tangible. Reaffirmed ₹300 Cr EBITDA as floor language (vs prior ceiling language).
FY'28 targets soft-introduced
New₹1,500 Cr revenue, ₹450 Cr EBITDA targets (Q&A mention, not formal guidance). Implies ~17% EBITDA growth FY27→FY28.
Organic growth skepticism rises
DowngradeAnalysts (Vikas Mhatre) pushed back: 'only missing is organic growth.' Management acknowledged aspiration to push higher but no concrete plan.
The Q&A
Analysts pressed on organic growth (Vikas Mhatre: low-teens ex-Unbound, should be higher teens) and client count drop (QoQ 906→841). Management held firm on margins/execution but defensive on organic, acknowledging need to accelerate. Tone slightly cautious when challenged on scale-up ability.
Headcount & quality — Krushi Parekh, BugleRock
AnsweredCuts were structural redundancy and variable capacity shift. Senior bench untouched. Margin expanded 16.9%→25.3% without rework/escalations.
Client count decline — Kashish Mehta, Dolat Capital
AnsweredOnly pruning is AJE by design. No other pruning in business.
Organic growth gap — Vikas Mhatre, Moonshot Ventures
PartialNot settling for achieved organic. Aspire to outperform markets. Corp Learning needs catch-up (market 12-13%, MPS 6-7%).
Unbound run-rate trajectory — Mahesh BP, Individual Investor
Answered$800K/month, 18-20% margin. Climb to Rule of 40 (mid-20s EBITDA) with growth, then Rule of 50.
M&A strategy shift — Vikas Mhatre, Moonshot Ventures
AnsweredDistressed highly accretive (>30% ROCE) but distracted from organic growth. Pivot to 3-yr 10%+ CAGR assets with 5-15% EBITDA, improve to 30% at MPS.
AI defensibility per segment — Kaushik Jhawar, AK Investment
AnsweredUnbound Intelligence (proprietary medical content, not web-scraped); DigiCore + Research Integrity (AI production); BridgeAI (corporate learning). All deployed at scale.
Guidance
FY'27: ~₹900-950 Cr implied from ₹300 Cr EBITDA @ 31-33% margin
MediumReaffirmed prior ₹300 Cr EBITDA floor. Q1 ₹224.2 Cr annualizes to ~₹900-950 Cr at sustained 31-33% margin rate.
FY'27 EBITDA margin: maintain 31-33% range
HighQ1 at 34.3%, likely peaked from AJE reset & one-time efficiencies. Guidance floor ₹300 Cr implies 31-33% @ ~₹900-950 Cr revenue.
Risks the call surfaced
Organic growth pressure
MediumCorp Learning only 6.9% YoY vs 12% steady-state target. Research/Education outperforming market but not aggressively. Ex-Unbound, organic in low-teens.
Unbound integration
MediumUnbound first full quarter in base. Must scale from $800K/month to $1M+/month, hit Rule of 40 (mid-20s margin) then Rule of 50. Synergies with Liberate unproven.
Customer concentration
MediumDespite Unbound add, top customers still material. Call did not disclose % from top 5/10 customers. Unbound's institutional base (medical schools, hospitals, libraries) broad but renewable contracts could face budget pressures.
Forex volatility
LowResearch & Education have material North America exposure. Q1 benefited from INR weakness (not quantified). Strengthening INR would pressure margins and reported growth.
AI commoditization risk
LowGeneric LLM models improving rapidly. MPS's moat is 'last mile' (trust, outcomes, domain context, verification). But if better models emerge, defensibility erodes.
Management
Score 7/10. Clear, structured call. CEO broke down Q1 into 4 segment perspectives (Research, Education, Corp Learning, Unbound). Transparent on AJE reset, headcount changes, acquisition strategy. Slightly defensive when pushed on organic growth; acknowledged need to accelerate but no concrete plan. Delivered on Q1 targets; EBITDA margin +730 bps YoY is real. Research 13% (core 26% ex-AJE), Education 42% (inc. Unbound), Corp Learning margin +830 bps. But organic growth ex-Unbound still low-teens, lagging prior 20%+ trajectory.
1 · Q2 FY27
AJE stabilization, Unbound synergy ramp testing
2 · H2 FY27
Corp Learning organic growth acceleration test, journal accessibility rollout
3 · FY28
Unbound full-year contribution, formal FY'28 guidance confirmation
Conviction present but execution risk on organic acceleration remains key dependency.
MPS Q1: consolidated PAT ₹50.4 Cr, +43% YoY; margins expand, Corporate Learning turns
PAT +43% YoY · revenue +20.4% · margins expanding · inline vs street
₹224.24 Cr
+20.4% YoY
₹50.39 Cr
+43% YoY
22.18%
+4pp YoY
₹29.7
MPS Limited opened FY27 with a broad-based beat: consolidated revenue of ₹224.2 Cr grew 20.4% YoY (9.3% QoQ) and net profit rose to ₹50.4 Cr, up 43.0% YoY (7.1% QoQ), lifting EPS to ₹29.70 from ₹20.78 a year ago. With no exceptional items on either side of the comparison bar a tiny ₹0.63 Cr prior-year restructuring loss, the underlying growth (~40% adjusted) is essentially the reported number — this is a genuinely strong print, not an accounting artifact. Revenue landed at the upper end of the only public model (Univest's ₹201–232 Cr trailing-growth range); there is no formal brokerage consensus for this small/mid-cap, so treat the beat as against a mechanical estimate rather than a street poll.
Q1 FY-2027 vs prior quarters
The quality is in the margins. Net profit margin expanded to 22.5% from 18.2% a year ago (roughly flat vs 22.2% last quarter), and operating profitability widened sharply — Q1 EBITDA of ~₹77 Cr implies an OPM near 34% against 26.7% in Q1 FY26 — as employee cost was held nearly flat YoY (₹83.9 Cr vs ₹82.0 Cr) while revenue climbed. Segmentally, the turnaround management flagged on the Q4 concall is visible: Corporate Learning segment result more than doubled to ₹5.1 Cr from ₹2.5 Cr on revenue of ₹27.6 Cr, Education solutions revenue jumped 42% YoY to ₹73.4 Cr (aided by the Feb-2026 Unbound Medicine acquisition), and Research solutions grew ~13% to ₹123.2 Cr. Standalone tells the same story (revenue ₹124.4 Cr, PAT ₹41.0 Cr, +42.5% YoY), so the two bases do not diverge materially.
The stock went into the print at ₹2,137.1, up 18.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management provided a strong outlook for FY'27, projecting EBITDA to comfortably cross INR 300 crores, implying a 3-year EBITDA CAGR of approximately 21%. This guidance is built bottom-up from operating plans and reflects current momentum, not a step change. The company anticipates continued revenue growth across its R
— This quarter: met
Against guidance, the quarter is on track: management guided FY27 EBITDA to comfortably cross ₹300 Cr, and a ~₹77 Cr Q1 run-rate annualises to ~₹308 Cr, with the Unbound margin-accretion thesis (targeted 25–30% exit EBITDA margin) consistent with the OPM already printed. Alongside results, the board approved a small (up to ₹1 Cr) wholly owned Singapore subsidiary — immaterial to numbers, framed as an APAC go-to-market base — and the ADI BPO amalgamation cleared a key hurdle, with NCLT-directed shareholder/creditor meetings set for 22 August 2026 (no accounting effect taken yet). A CRO appointment rounds out the board actions. The read into Q2: margin durability as Unbound integrates and whether Corporate Learning's turnaround holds sequentially.
What to watch
W1
Whether Q1 OPM of ~34% holds as Unbound Medicine integrates — management targets a 25–30% exit-FY27 EBITDA margin
W2
Corporate Learning durability: segment result doubled YoY to ₹5.1 Cr; needs to sustain sequentially for the turnaround to stick
W3
FY27 EBITDA >₹300 Cr guidance checkpoint — Q1 run-rate ~₹308 Cr leaves little cushion if H2 softens
W4
ADI BPO amalgamation: NCLT shareholder/creditor meetings on 22 Aug 2026 — sanction would change the reporting entity
Clean machine-readable filing in INR lacs (÷100 to Cr). No exceptional items this quarter (consolidated or standalone); year-ago Q1 FY26 carried a small ₹0.63 Cr AJE restructuring loss. Consolidated includes 2 foreign subs reviewed by other auditors; MPS Employee Welfare Trust (net loss ₹0.32 Cr) unreviewed but immaterial.